New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
09:10 EDTAPPY, APPY, SNTI, SNTI, AEMD, AEMD, INO, INOPR Newswires to host a virtual conference
RetailInvestorConference is being held on February 7 with webcasted company presentations to begin at 9:15 am. Webcast Link
News For APPY;SNTI;AEMD;INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 13, 2015
09:32 EDTAEMDAethlon Medical announces Health Canada approval of Ebola treatment protocol
Aethlon Medical disclosed that the Medical Devices Bureau of Health Canada has approved a clinical study protocol to treat Ebola-infected individuals with the Aethlon Hemopurifier. The protocol allows for an investigational study of Hemopurifier therapy to be conducted in up to 3 human subjects. The objective of the study is to standardize and evaluate the use of the Hemopurifier as supportive care in the treatment of EVD. "There is no assurance that the investigational study will result in the collection of clinical data that would support Health Canada licensing requirements," the company said.
May 12, 2015
08:10 EDTAEMDAethlon Medical announces IRB approval of cancer study
Aethlon Medical announced that the Institutional Review Board of the University of California, Irvine has approved a multi-indication clinical study entitled, "Plasma Exosome Concentration in Cancer Patients Undergoing Treatment." Aethlon previously disclosed that it had entered into investigator-initiated clinical trial agreement with UCI, which was pending IRB approval. Under the approved clinical protocol, the study will seek to enroll five individuals in each of nine defined tumor types for a total study population of up to 45 subjects. The study endpoints include establishing baseline exosome levels and monitoring changes in circulating exosome concentration associated with tumor treatment and the association of longitudinal changes in circulating exosome concentrations with response to treatment. Recruitment of participants in the study will be through the use of internal and outside referrals to the University of California, Irvine Medical Center. The clinical study will also provide data to help direct future clinical investigations of the Aethlon Hemopurifier as a therapeutic candidate to reduce the presence of circulating tumor-derived exosomes, which are known to suppress the immune system of cancer patients and contribute to the spread of metastasis.
05:32 EDTINOInovio initiates clinical trial with DNA immunotherapies to treat ebola
Subscribe for More Information
May 11, 2015
07:16 EDTINOInovio reports Q1 EPS (18c), consensus 1c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use